Vascular - Critical Limb Ischemia (CLI) | |
|---|---|
| Study Name | Principal Investigator |
| SAVAL – A phase 3, global, prospective, multicenter, 2:1 randomized trial evaluating the safety
and effectiveness of the DES BTK Vascular Stent System compared to standard percutaneous
transluminal angioplasty to treat infrapopliteal artery lesions in subjects with critical limb
ischemia(CLI). Read more. |
John Rundback, MD |
| Abbott LIFE-BTK – Pivotal Investigation of Safety and Efficacy of BRS Treatment (Below the Knee) Randomized Controlled Trial. Read more. |
John Rundback, MD |
Vascular - Native Arteriovenous Dialysis Fistulae (AVF) | |
| Study Name | Principal Investigator |
| APV-IN.PACT AV Access – A randomized Study of IN.PACT™ AV Access Paclitaxel-Coated Percutaneous Transluminal Angioplasty (PTA) Balloon vs. Standard PTA for the Treatment of Obstructive Lesions in the Native Arteriovenous Dialysis Fistulae (AVF). Read more. |
Vincent Gallo, MD |
| TOBA II BTK – Tack Optimized Balloon Angioplasty study for the below the knee arteries using
the Tack Endovascular System TM. Read more. |
John Rundback, MD |
Vascular - Peripheral Artery Disease (PAD) | |
| Study Name | Principal Investigator |
| TRANSCEND – SurVeil™ Drug-Coated Balloon – A prospective, multi-center, single-blind,
randomized, controlled, noninferiority clinical trial. The trial will randomize subjects with
symptomatic PAD due to stenosis of the femoral and/or popliteal arteries. Subjects meeting
eligibility criteria will be randomized 1:1 to treatment with either the SurVeil DCB or the IN.PACT
Admiral DCB. Read more. |
John Rundback, MD |
| OSPREY ILIAC – TIS2015-01 – Occlusive/Stenotic Peripheral artery Revascularization Study for Common and/or External Iliac Artery Using the Misago® RX Self-expanding Peripheral Stent. Read more. |
John Rundback, MD |
Vascular - Venous Insufficiency | |
| Study Name | Principal Investigator |
| Vesper V-CA-001 – Venous Stent for the Iliofemoral Vein Investigational Clinical Trial Using the DUO Venous Stent System (VIVID) Read more. |
John Rundback, MD |
